ASH congresses2021-02-23T15:46:59+01:00

ASH 2020 – virtual

Lecture Board: Paul Barr, MD; Chan Cheah, MBBS; Paolo Ghia, MD, PhD; Preetesh Jain, MD, PhD; Stephen Opat, MD; Kerry Rogers, MD; Alessandra Tedeschi, MD
Medical Writer: Dr. Judith Moser

Preface – ASH 2020

Preface – ASH 2020 Heinz Ludwig, MD, Director of the Wilhelminen Cancer Research Institute, Department of Medicine I, Center for Oncology, Hematology and Palliative Care, Wilhelminen Hospital, Vienna, Austria Dear Colleagues, The ASH Annual Meeting and Exposition is the premier event for presentation of novel data on malignant and non-malignant hematologic diseases, attracting up to 30,000 specialists from all over the world.

What is new in Waldenström’s macroglobulinemia?

What is new in Waldenström’s macroglobulinemia? Constitutive activation of the Bruton’s tyrosine kinase (BTK) pathway has been shown to induce malignant cell survival in patients with Waldenström’s macroglobulinemia (WM) [1, 2].

Management of CLL patients: BTK inhibition and beyond

Management of CLL patients: BTK inhibition and beyond BTK inhibitors, the Bcl-2 inhibitor venetoclax and anti-CD20 antibodies such as obinutuzumab have dramatically changed the therapeutic landscape of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Advancing treatment in patients with mantle cell lymphoma

Advancing treatment in patients with mantle cell lymphoma Update on acalabrutinib monotherapy High relapse rates after standard-of-care regimens in the frontline setting are typical of mantle cell lymphoma (MCL), which is an aggressive, rare, B-cell Non-Hodgkin lymphoma [1-4].

Finding the way among a multitude of targets and regimens

Finding the way among a multitude of targets and regimens Stephen Opat, MD,  School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia Under which conditions might patients with chronic lymphocytic leukemia achieve long-term treatment-free remission?

Bone marrow microenvironment: culprit and target

Bone marrow microenvironment: culprit and target  Jorge J. Castillo, MD, Dana-Farber Cancer Institute, Boston, USA Apart from factors such as genetic events that contribute to the malignant transformation in Waldenström’s macroglobulinemia (WM), the bone marrow microenvironment has been identified as a crucial player in WM disease progression [1].


All downloads from ASH 2020

ASH 2020 virtual - Slidekit

Slidekit BTK inhibition in B-Cell Malignancies

ASH 2020 virtual - Congress Report

Full report (english)


All videointerviews from ASH 2020

Steven P. Treon explains about innovative approaches in the treatment of Waldenström’s macroglobulinemia, future aspects and the successful use of BTK inhibition within niche groups of patients with WM, and potential benefits of BTK inhibitors regarding COVID-19 complications.

Jorge Castillo relates to recent developments with respect to follicular lymphoma, multiple myeloma and Waldenström’s macroglobulinemia, current insights into CAR-T cell therapy in the setting of multiple myeloma, and the future of anti-CD38 antibody treatment in patients with Waldenström’s macroglobulinemia.

Alessandra Tedeschi summarizes the results from the MAGNOLIA and iNNOVATE trials, relates to recent advances in the management of marginal zone lymphoma and discusses the effect of the introduction of BTK inhibition on the prognosis of patients with Waldenström’s macroglobulinemia.

Stephen Opat discusses the requirements for treatment-free long-term remission in the setting of CLL and talks about the future of BTK inhibitors and promising combinations in B-cell malignancies in general, as well as the strengths and limitations of immune checkpoint inhibitors.